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ABSTRACT The current tuberculosis (TB) vaccine, Mycobacterium bovis Bacillus Calmette-Guérin (BCG), provides insufficient
protection against pulmonary TB. Previously, we generated a listeriolysin-expressing recombinant BCG strain, which to date has
successfully completed phase I and phase IIa clinical trials. In an attempt to further improve efficacy, we deleted the antiapop-
totic virulence gene nuoG, encoding NADH dehydrogenase 1 subunit G, from BCGureC::hly. In vitro, deletion of nuoG unex-
pectedly led to strongly increased recruitment of the autophagosome marker LC3 to the engulfed vaccine, suggesting that nuoG
also affects xenophagic pathways. In mice, BCGureC::hlynuoG vaccination was safer than BCG and improved protection
over that of parental BCGureC::hly, significantly reducing TB load in murine lungs, ameliorating pulmonary pathology, and
enhancing immune responses. Transcriptome analysis of draining lymph nodes after vaccination with either BCGureC::hly or
BCGureC::hlynuoG demonstrated earlier and stronger induction of immune responses than that with BCG SSI and sug-
gested upregulation of inflammasome activation and interferon-induced GTPases. In summary, BCGureC::hlynuoG is a
promising next-generation TB vaccine candidate with excellent efficacy and safety.
IMPORTANCE Autophagy and apoptosis are fundamental processes allowing cells to degrade their components or kill them-
selves, respectively. The immune system has adopted these mechanisms to eliminate intracellular pathogens. Residing in host
cells, the causative agent of TB, Mycobacterium tuberculosis, has evolved strategies to set cellular programs of autophagy and
apoptosis “on hold.” The mycobacterial gene nuoG was found to prevent host cell apoptosis. We have deleted nuoG in the live
vaccine candidate BCGureC::hly, which is in phase II clinical development, to leave cellular apoptosis “on go” upon immuni-
zation. In preclinical models, this strategy boosted immunity and improved protection from M. tuberculosis infection. Unex-
pectedly, we obtained compelling evidence that mycobacterial nuoG facilitates inhibition of autophagic pathways, suggesting a
new role for this gene in the host-pathogen interplay in TB.
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Tuberculosis (TB) remains a global health burden (1). The TBvaccine Mycobacterium bovis bacillus Calmette-Guérin
(BCG), which was attenuated by serial passage of the pathogen M.
bovis, entered clinical practice in 1924 (2). BCG has contributed to
reduction of childhood mortality and is relatively safe in immu-
nocompetent individuals. However, it fails to prevent the most
prevalent form of disease, pulmonary TB, and disease transmis-
sion and carries an increased risk of adverse events in HIV in-
fants (3, 4). Previously, we developed a recombinant derivative,
BCG ureC::hly, with significantly improved protective efficacy
and safety in mice by secretion of listeriolysin O, a pore-forming
protein of Listeria monocytogenes (5–7). The vaccine has success-
fully completed phase I and IIa clinical trials (NCT01479972,
NCT01113281, and NCT00749034), demonstrating its safety and
immunogenicity in adults and infants (8, 9). In vitro, BCGureC::
hly induced increased apoptosis, inflammasome activation, and
expression of microtubule-associated protein light chain 3 (LC3)
(7, 8). In mice, BCG ureC::hly induced increased central mem-
ory CD4T cells with protective capacity and expression of IL-1,
IL-18, and Tmem173 (STING) (6, 7).
Immune cells have adopted crucial processes, such as pro-
grammed cell death (apoptosis) and intracellular degradation of
host cell compartments (autophagy), for antimicrobial defense
(10). Selective autophagy, also termed xenophagy, in which cells
direct autophagic pathways against pathogens, is a mechanism of
intracellular killing of Mycobacterium tuberculosis (11–13) and
also promotes antigen presentation (14). After M. tuberculosis in-
fection, bacterial DNA and proteins translocate into the host cell
cytosol by the Mycobacterium-specific type VII secretion system,
Esx-1, and they are subsequently recognized by autophagy recep-
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tors p62 and Ndp51 (11–13). BCG lacks Esx-1, does not rupture
the phagosome, and is not targeted by autophagy under normal
conditions (7, 11, 14, 15). Apoptosis controls M. tuberculosis rep-
lication and spreading (16), while phagocytosis of apoptotic host
cell-derived vesicles by dendritic cells boosts T cell responses via
cross-presentation (17). M. tuberculosis has evolved strategies to
inhibit these defense mechanisms. Screening for antiapoptotic
genes inM. tuberculosis identified nuoG, encoding a subunit of the
dispensable respiratory enzyme complex NADH dehydrogenase 1
(18, 19). Disruption of nuoG increased M. tuberculosis-induced
apoptosis via a tumor necrosis factor alpha (TNF-)-dependent
mechanism and decreased the virulence ofM. tuberculosis (18). As
apoptosis is thought to enhance adaptive immune responses
through cross-presentation (17, 20, 21), we deleted nuoG in BCG
ureC::hly. We were able to surmount the high bar, further in-
creasing efficacy against TB in a vaccine that already expresses
100-fold-higher protection than BCG, without loss of its excellent
safety profile.
RESULTS
Disruption of nuoG in BCG and BCG ureC::hly induces co-
localization of bacteria with the autophagosomal marker
LC3. We deleted nuoG from BCG ureC::hly in an attempt to
further improve vaccine efficacy by enhancing apoptosis. Previ-
ously, Velmurugan et al. showed increased apoptosis in THP-1
macrophages following deletion of the nuoG gene from M. tuber-
culosis (19). Here, disruption of nuoG in BCG and BCGureC::hly
did not increase apoptosis of infected THP-1 macrophages at 24 h
or 48 h postinfection (p.i.), although both listeriolysin-expressing
strains, BCG ureC::hly and its nuoG-deficient derivative, tended
to induce more apoptosis than BCG (Fig. 1A). After vaccination
of mice with BCG ureC::hly and BCG ureC::hly nuoG,
numbers of apoptotic cells remained unchanged in draining
lymph nodes (dLNs) compared to BCG-vaccinated mice at
early time points (Fig. 1B and C). However, by day 14, both
BCG ureC::hly and BCG ureC::hly nuoG significantly in-
FIG 1 Effect of mycobacterial nuoG deletion on apoptosis of host THP-1 macrophages and in lymph nodes of vaccinated mice. (A) Percentages of caspase-3/7
BCG THP-1 macrophages were quantified in triplicate samples at 24 h and 48 h by ArrayScan after infection with PKH26-labeled BCG, BCG nuoG, BCG
ureC::hly, and BCGureC::hlynuoG (MOI of 20) for 4 h. Results are representative of three experiments. (B) TUNEL staining of lymph node sections at days
3, 7, and 14 postvaccination. A lymph node from an M. tuberculosis-infected mouse was used as a positive control. Purple spots are TUNEL (apoptotic cells).
Cell nuclei were stained with 4=,6-diamidino-2-phenylindole. (C) Quantification of apoptotic cells in lymph nodes at days 7 and 14 postvaccination. TUNEL
cells per field of view at 20 (n 3 mice; both dLNs) were counted. Results are representative of two experiments. Data were analyzed using one-way ANOVA
with Tukey’s multiple-comparison test. *, P 0.05; **, P 0.01; ***, P 0.001.
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creased apoptosis in comparison to BCG, which was further
enhanced in the absence of nuoG, suggesting a downstream
effect on apoptosis (Fig. 1B and C).
Further experiments in THP-1 macrophages demonstrated
that, unexpectedly, knockout of nuoG from BCG strains drasti-
cally enhanced colocalization of the vaccine with the autophagy
protein LC3 (Fig. 2A), from 4 to 8 h p.i. up to 48 h p.i. (Fig. 2A and
B). While LC3 was previously shown to be increased in THP-1
macrophages after BCGureC::hly infection (7), it did not specif-
ically colocalize with the vaccine as seen after infection with BCG
ureC::hly nuoG. This suggests an intriguing new role for the
mycobacterial gene nuoG in suppressing host cell xenophagic re-
sponses, which may involve either the canonical autophagy path-
way or LC3-associated phagocytosis (LAP), two mechanistically
distinct processes involving autophagy proteins (22, 23).
Deletion of nuoG improves vaccine-induced protection. To
assess the specific influence of nuoG deletion on vaccine efficacy,
we immunized mice with BCG nuoG and determined bacterial
loads over 180 days post-M. tuberculosis challenge (Fig. 3A). Vac-
cination with BCG nuoG consistently reduced the M. tuberculo-
sis burden in lungs of mice over that after vaccination of mice with
BCG SSI, with a similar, less pronounced trend in spleens
(Fig. 3B). Having demonstrated that nuoG disruption improved
protective efficacy, we then investigated whether this effect syner-
gizes with the apoptosis-inducing phenotype of BCG ureC::hly.
Consistent with previous reports, BCG ureC::hly-vaccinated
mice were better protected than BCG SSI-vaccinated mice (Fig. 4A
and B) (5, 24). Importantly, additional deletion of nuoG further
improved efficacy against challenge with both an M. tuberculosis
laboratory strain (H37Rv) (Fig. 4A) and a clinical M. tuberculosis
isolate (Beijing/W lineage) (Fig. 4B). Protection was particularly
improved in lungs, which also benefited from markedly amelio-
rated gross pathology (Fig. 4C) and histopathology (Fig. 4D) at
180 days p.i. Differences in bacterial counts were less pronounced
but statistically significant in spleens (Fig. 4A and B). Thus, BCG
ureC::hly nuoG conferred increased protection compared not
only to BCG but also to BCG ureC::hly, against both pulmonary
and disseminated TB. In order to assess the safety of the recombi-
nant BCG vaccine candidates, we examined persistence and dis-
semination in the months following vaccination. The two recom-
binant vaccine candidates were comparable, i.e., more quickly
cleared from the lymph nodes than BCG SSI and with lower de-
grees of dissemination to the spleen and no dissemination to the
lung (see Fig. S1 in the supplemental material). Attenuation of the
recombinant strains compared to BCG SSI was confirmed by
FIG 2 Deletion of nuoG from BCG and BCG ureC::hly leads to increased
association of LC3 with engulfed bacteria in THP-1 macrophages. (A) LC3
staining (green) in THP-1 macrophages infected with PKH26-labeled BCG
SSI, BCGnuoG, BCGureC::hly, and BCGureC::hlynuoG (red), 24 h p.i.
Nuclei are stained with Hoechst stain (blue). Results are representative of three
experiments. (Top) Bar, 10 m; (bottom) cropped images showing a single
cell. (B) Autophagy quantification in THP-1 macrophages at 8 and 24 h p.i.
Individual points represent the percentages of 25 infected cells containing
LC3-associated bacteria, and 300 cells were counted per group. Two experi-
ments. Data were analyzed using one-way ANOVA with Tukey’s multiple-
comparison test. ***, P 0.001.
FIG 3 Deletion of nuoG in BCG improves protection of mice against TB. (A) Schematic design of protection studies. (B) Mice vaccinated subcutaneously with
phosphate-buffered saline (PBS;), BCG SSI (), or BCG nuoG () were aerosol infected after 90 days with a low dose of 100 to 200 CFU of M. tuberculosis
laboratory strain H37Rv. Bacterial burdens of lungs and spleen were determined at 30 and 180 days postchallenge by plating organ homogenates on agar. Shown
are means standard deviations. Results are representative of two experiments. Data were analyzed using one-way ANOVA with Tukey’s multiple-comparison
test (n 8). *, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001.
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studies in severe combined immunodeficiency (SCID) mice, in
which BCG ureC::hly- and BCG ureC::hly nuoG-vaccinated
mice survived twice as long as BCG SSI-vaccinated animals. To-
gether, our data demonstrate that deletion of nuoG sustained the
notable preclinical safety profile of BCG ureC::hly (Fig. 4E) (5).
In summary, deletion of nuoG from BCG ureC::hly improved
efficacy against TB, paralleled by excellent safety.
Vaccination with BCGureC::hlynuoG enhanced immune
responses. Because BCG ureC::hly nuoG-vaccinated mice had
the lowest bacterial burdens following M. tuberculosis challenge,
we aimed to determine which immune responses were associated
with protection. The more rapid increase in size of dLNs of BCG
ureC::hlynuoG-vaccinated mice in the days following vaccina-
tion suggested increased stimulation of the acquired immune re-
sponse (Fig. 5A). Previously, we had demonstrated significantly
increased Ag85B-specific central memory CD4T cells in dLNs of
BCG ureC::hly-vaccinated mice compared to BCG SSI-
vaccinated mice at 14 days (6), and here, we observed the same
trend, with similar numbers of Ag85B-specific CD4 T cells in
BCG ureC::hly nuoG-vaccinated mice at day 14 (Fig. 5B). In
addition, at day 21, frequencies were significantly increased for T
follicular helper cells (Fig. 5C), central memory and effector mem-
ory CD4T cells (Fig. 5D and E), germinal center B cells (Fig. 5F),
and gamma interferon (IFN-)-producing CD4T cells (Fig. 5G)
in dLNs of BCG ureC::hly nuoG-vaccinated mice compared to
BCG SSI-vaccinated mice. No significant effect was found in fre-
quencies of central memory and effector memory CD8 T cells
(Fig. 5H and I) in comparison to BCG SSI-vaccinated mice
(Fig. 5B). Frequencies of T follicular helper cells, effector memory
CD4 T cells, and IFN--producing CD4 T cells were also in-
creased in spleens of BCG ureC::hly nuoG-vaccinated mice
compared to BCG SSI-vaccinated mice, whereas germinal center
B cells, central memory CD4 T cells, and central and effector
memory CD8T cells were not significantly different (see Fig. S2A
to G in the supplemental material). Mycobacterium-specific im-
munoglobulin G (IgG) levels (Fig. 5J) were markedly increased
after vaccination with both recombinant strains compared to vac-
cination with the current vaccine strain BCG SSI. We have already
observed higher antibody levels induced by BCG ureC::hly than
by BCG, both in mice and in humans (6, 8). Overall, the trend was
qualitatively similar for the two recombinant BCG strains, but
BCG ureC::hly nuoG-vaccinated mice had increased CD4 T
cell responses compared to BCG ureC::hly-vaccinated mice, as
well as increased germinal center B cells, suggesting synergism
between the mechanisms of efficacy of the two genetic strain mod-
ifications.
Gene expression analysis of dLNs in BCG ureC::hly- and
BCG ureC::hly nuoG-vaccinated mice. Microarray analyses
FIG 4 Deletion of nuoG in the clinical vaccine candidate, BCG ureC::hly, further improves long-term protection against TB. (A and B) Mice vaccinated
subcutaneously with phosphate-buffered saline (PBS;), BCG SSI (), BCGureC::hly (Œ), or BCGureC::hlynuoG (}) were aerosol infected after 90 days
with a low dose of 100 to 200 CFU of M. tuberculosis laboratory strain H37Rv (n 5 to 6) per animal (A) or a clinical isolate of the Beijing/W lineage (n 7) (B).
Bacterial burdens of organs were assessed at designated time points p.i. by plating organ homogenates. Shown are means  standard deviations. Results are
representative of three (A) or two (B) experiments. Data were analyzed using one-way ANOVA with Tukey’s multiple-comparison test. (C) Gross pathology of
left lung lobe from three out of six vaccinated mice 180 days p.i. with M. tuberculosis H37Rv. Bar, 5 mm. Results are representative of two experiments. (D)
Pulmonary histopathology of the left lung lobe from vaccinated mice 180 days p.i. withM. tuberculosisH37Rv. Lungs were fixed and embedded, and sections were
stained with H&E prior to examination. Bar, 1 mm. Results are representative of two experiments. (E) Survival of SCID mice after subcutaneous administration
of 106 CFU of indicated strains was monitored over time. Median survival calculated by Mantel-Cox log rank test was 181.5 days (BCG SSI), 398 days (BCG
ureC::hly), and 405 days (BCG ureC::hly nuoG). Results are representative of two experiments. *, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001.
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were performed to assess global host gene expression profiles in
dLNs of mice in response to vaccination (Fig. 5K). Overall, results
revealed earlier and stronger induction of immune responses by
both recombinant BCG strains, particularly BCG ureC::hly
nuoG, with vastly more genes differentially expressed (P 0.05;
fold change,2) than after BCG vaccination (see Fig. S3A in the
supplemental material). Genes in R1- to R8-labeled gene clusters
are listed in Table S1 in the supplemental material. Because BCG
ureC::hly nuoG was derived from BCG ureC::hly, numerous
genes showed similar expression patterns in response to the two
vaccine strains compared to BCG, e.g., IL-1 and IL-18, previ-
ously found to be upregulated 1 day after BCG ureC::hly vacci-
nation (7) (see Fig. S3B and C). In contrast, gene expression levels
of IFN-inducible GTPases (Gbps, Irgs, and Givns), often associ-
ated with phagosomal or autophagic vacuoles and inflammasome
activation (25–28), and ubiquilin, a key player in xenophagic re-
FIG 5 Enhanced immune responses after vaccination with BCG ureC::hly and BCG ureC::hly nuoG compared to BCG SSI. (A) Lymph nodes stained with
H&E (n 4 or 5, two experiments). Bar, 1 mm. (B) Frequencies of Ag85B CD4 T cells at day 14 postvaccination. (C to F) Frequencies of T follicular helper
(TFH) cells (C), CD4 central memory T (TCM) cells (D), effector memory CD4 T (TEM) cells (E), and germinal center (GC) B cells (F). Two experiments;
n  7 to 8. (G) Frequencies of gamma-interferon-positive (IFN-) CD4 T cells were measured in dLNs by intracellular cytokine staining following
restimulation with M. tuberculosis. n 8; two experiments. (H and I) CD8 TCM (H) and CD8 TEM (I) cells at 21 days postvaccination. (J) Mycobacterium-
specific IgG in the serum at 21 days postvaccination. Three experiments; n 9 to 11. Data from multiple experiments were analyzed using two-way ANOVA with
Tukey’s multiple-comparison test. Unless indicated by brackets, P values compare with unvaccinated controls. *, P 0.05; **, P 0.01; ***, P 0.001. (K) Heat
map showing cluster analysis of differentially regulated (P 0.05, 2-fold or greater difference) genes in dLNs of vaccinated mice (n 4 to 5) versus naive controls
(n  4). Microarray data were analyzed using GeneSpring 12.6 GX (Agilent Technologies), with quality control filters, normalization, and one-way ANOVA.
(R1) Cell cycle, mitosis, DNA replication/repair, proliferation. (R2) Antimicrobial responses, metabolism, proliferation. (R3) Regulation of apoptosis, endo-
plasmic reticulum (ER) genes, pathogen response, antibody production. (R4) IFN-induced genes. (R5) Inflammation, neutrophils, myeloid cells, adhesion. (R6)
Lipid/glucose metabolism. (R7) Lipid binding, Wnt signaling network. (R8) Cell signaling (details in Table S1 in the supplemental material).
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sponses to M. tuberculosis (13), were increased at earlier time
points and to greater levels in BCG ureC::hly nuoG-vaccinated
mice (see Fig. S3C), which is in line with the observed increase in
bacterium-associated LC3 responses in vitro. Table S2 in the sup-
plemental material lists genes significantly upregulated (P 0.05)
2-fold versus the naive group specifically in BCG ureC::hly
nuoG-immunized mice at days 1, 3, and 7 postvaccination. By
day 7, expression of IFN-inducible GTPases had also increased in
BCG- and BCGureC::hly-vaccinated mice but tended to remain
slightly lower than that after BCG ureC::hly nuoG vaccination
in most cases (see Fig. S4). Early upregulation of genes for
inflammasome-associated interleukin-1 (IL-1), IL-18, cytoso-
lic DNA sensor Ifi204, and Gbps was confirmed by reverse
transcription-PCR (RT-PCR) (see Fig. S5). Gene ontology (GO)
analysis of differentially expressed genes highlighted involvement
of acute inflammatory responses at day 1 postvaccination and
immune cell activation and differentiation at day 3, while concur-
rently with enhanced dLN enlargement in BCG ureC::hly
nuoG-vaccinated mice, cell cycle and developmental pathways
featured prominently at days 3 and 7 (see Table S3). Due to the
overwhelming dominance of cell cycle and tissue development
pathways obtained in GO analysis of day 7 gene expression, only
the top 20 pathways are listed in the table.
DISCUSSION
An estimated 9.6 million new active TB cases and 1.5 million
deaths occurred in 2014 (1), emphasizing the need for a more
efficacious vaccine. The current TB vaccine, BCG, shows vari-
able efficacy against the pulmonary form of the disease, al-
though it has 60 to 80% protective efficacy against severe dis-
seminated forms of disease in infants, such as meningitis (29).
A recombinant live vaccine, BCGureC::hly, which expresses list-
eriolysin, is the most advanced BCG replacement vaccine candi-
date in clinical trials, having completed phase I and phase IIa
safety and immunogenicity trials successfully (NCT01479972,
NCT01113281, and NCT00749034) and currently undergoing a
phase II safety and immunogenicity trial in HIV-exposed new-
borns (NCT02391415). Our previous studies suggest that in-
creased preclinical efficacy of BCG ureC::hly is based on (i) high
egression of BCG-derived protein antigens and (ii) release of bac-
terial DNA into the host cell cytosol, subsequent induction of
apoptosis and inflammasome activation, and increased genera-
tion of central memory CD4 T cell responses (6–8). While this
vaccine awaits phase IIb efficacy trials, next-generation vaccines
are being designed and tested in preclinical models aimed at op-
timizing efficacy and/or safety.
Recently, an antiapoptotic virulence gene, nuoG, was identified
in M. tuberculosis (18, 19). As apoptosis is thought to enhance
adaptive immune responses through cross-presentation (17, 20,
21), we aimed to augment the efficacy and safety of BCG ureC::
hly by deleting nuoG. Because BCG ureC::hly already induces
100-fold-better protection than the sham control and 10-fold pro-
tection over BCG in mice, which has not been achieved by other
recombinant BCG vaccine candidates to date (5, 24), it sets a high
bar for further improvement. Yet, our results demonstrate that
vaccination with BCG ureC::hly nuoG further increased pro-
tection about 5-fold in lungs of mice challenged with the M. tu-
berculosis laboratory strain (H37Rv) and a clinical M. tuberculosis
isolate (Beijing/W lineage) at 90 and 180 days p.i. while maintain-
ing excellent safety in immunodeficient SCID mice. Note that in-
creased protection was sustained against the clinical isolate M.
tuberculosis Beijing/W, which is considered notoriously resistant
against BCG vaccination. Deletion of nuoG from unmodified
BCG also resulted in decreased pulmonary pathogen loads, sug-
gesting a standalone function for nuoG in protective efficacy.
The increased efficacy of BCG ureC::hly nuoG versus BCG
ureC::hly was associated with a numerical increase in CD4 TEM
cells, TFH cells, and germinal center B cells and a trend toward an
increase of CD4 TCM cells. TEM cells, which appear early after
infection and can secrete effector cytokines such as IFN- and
tumor necrosis factor alpha (TNF-), provide immediate protec-
tion, while TCM cells proliferate in the LN and generate new waves
of effector cells upon reexposure to antigen (6, 30, 31). Recently,
TCM cells were found to be associated with protection after vacci-
nation (6, 31). We demonstrated previously that vaccination with
BCGureC::hly increased TCM responses as well as TFH responses
and antibody production (6), and these responses seem to be fur-
ther enhanced after BCGureC::hlynuoG vaccination. Transfer
studies demonstrated that protection against TB was conferred by
the TCM cell population (6). Both TCM and TFH express CXCR5,
and CXCR5-expressing T cells have previously been correlated
with decreased lung pathology following vaccination and chal-
lenge with M. tuberculosis (32). The TFH population, which de-
creases more quickly than the long-lived TCM population, stimu-
lates germinal center B cell responses (33), but the role of B cells
and antibodies in TB remains unclear. Both TCM and TFH cells
have been associated with enhanced antibody responses (30). Vac-
cination with BCG ureC::hly and BCG ureC::hly nuoG leads
to increased antibody responses in mice, and enhanced produc-
tion of Mycobacterium-specific antibodies was found in a phase I
clinical trial in the BCGureC::hly group over the BCG group (8).
Although it is difficult to foresee a protective role of antibodies to
M. tuberculosis once it is hidden inside host cells, vaccine-induced
preexisting antibodies could participate in prevention of infection
with M. tuberculosis (34). Apart from their role in antibody pro-
duction, B cells can also present antigen to T cells and enhance
TCM and TFH cell development (35).
In accordance with improved immune responses, dLNs were
found to increase in size earlier in BCG ureC::hly nuoG-
vaccinated mice. Transcriptome analysis revealed similar changes
in gene expression in both BCG ureC::hly- and BCG ureC::hly
nuoG-vaccinated mice, with induction of genes such as IL-1,
IL-18, Gbps, and other GTPases, although the expression of genes
associated with GTPase activity, intracellular resistance, inflam-
matory responses, cell activation, and cell proliferation tended to
be higher in BCG ureC::hly nuoG-vaccinated mice. Genes sig-
nificantly differentially expressed between BCG ureC::hly
nuoG- and BCG ureC::hly-vaccinated mice included Ifng- and
IFN--induced genes, suggesting an improved antimicrobial
Th1-type response. Overall, nuoG deletion appeared to synergize
with, and enhance, the protective effects of the ureC::hly muta-
tion in BCG against M. tuberculosis, since most responses were
quantitatively but not qualitatively different. Unexpectedly, the
present study also uncovered a novel potential role for the myco-
bacterial gene nuoG in suppressing host cell LC3-mediated path-
ways, in addition to its previously reported role in inhibition of
apoptosis (18, 19). For analysis of nuoG-mediated effects, we em-
ployed THP-1 cells, shown to be an appropriate model for human
alveolar macrophage responses to mycobacterial infection (36)
and used for investigation of antiapoptotic functions of nuoG (18,
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19). Previously, we have shown that BCG ureC::hly induced in-
creased overall levels of the autophagy marker LC3 in infected
THP-1 cells in an AIM2- and STING-dependent manner com-
pared to BCG SSI (7). However, colocalization of LC3 with bac-
teria was not observed. Here, we demonstrate that both BCG and
BCG ureC::hly strains deficient in nuoG colocalized with LC3
within THP-1 cells, which did not occur in the parental strains.
This effect was observed to begin between 4 and 8 h p.i.; at 24 h p.i.,
most bacteria were completely surrounded by LC3, and up to 48 h
p.i., LC3 was still associated with the bacteria. It has been shown
that artificially inducing autophagy during BCG vaccination in-
creases antigen processing, leading to improved Th1 responses
and vaccine efficacy (14). It remains to be seen whether the strong
colocalization of the autophagy protein LC3 mediates enhanced
destruction of the bacteria through canonical autophagic path-
ways or through LAP pathways (22) and whether this provides a
link to the enhanced protective immune responses seen in BCG
ureC::hly nuoG-vaccinated mice. During autophagy, proteins
such as LC3 form a double-membraned autophagosome, which
captures cytoplasmic components and transports them to the ly-
sosome for degradation (37). During LAP, autophagy compo-
nents such as LC3 are translocated to the phagosomal membrane
and promote fusion with the lysosome, which does not involve the
formation of a double-membrane autophagosome (22). Conjuga-
tion of LC3 to phagosomes and subsequent association with lyso-
somes require the activity of NADPH oxidase (NOX2) and the
production of reactive oxygen species (ROS). Intriguingly, previ-
ous studies on nuoG in M. tuberculosis revealed that inhibition of
apoptosis was related to its ability to neutralize NOX2-dependent
ROS (18). Therefore, the ability of nuoG to neutralize NOX2-
dependent ROS could also impact the induction of LAP, explain-
ing why nuoG-deficient BCG has increased LC3 colocalized to
phagocytosed bacteria. NOX2 activity is also required for efficient
cross-presentation by human dendritic cells (38). Therefore, we
speculate that the nuoG gene ofM. tuberculosisplays multiple roles
in inhibiting optimal host immune responses and antigen presen-
tation.
The mechanism by which nuoG deletion leads to increased
targeting of the bacteria is curious, as it implies a role for nuoG in
inhibiting LAP, and possibly other autophagic pathways involving
LC3. However, BCG ureC::hly and BCG ureC::hly nuoG had
similarly decreased survival times and less dissemination in im-
munocompetent mice, suggesting that inflammasome- or
apoptosis-mediated mechanisms induced by both vaccine strains
are primarily responsible for eliminating BCG. Apoptosis of in-
fected macrophages is considered important for immunity to pul-
monary TB (18–20, 39). Similarly to M. tuberculosis (19), we
found that BCG did not induce elevated levels of apoptosis in
THP-1 macrophages, and deletion of nuoG did not enhance this.
As nuoG-inhibited apoptosis in M. tuberculosis relies on neutral-
ization of NOX2-dependent ROS (18), it is possible that nuoG-
deficient BCG induces lower levels of ROS. In vivo, apoptosis was
increased only at day 14 in mice vaccinated with BCG ureC::hly
nuoG, suggesting that increased apoptosis occurs downstream of
altered intracellular mechanisms initiated in the absence of nuoG,
including increased oxidative stress or autophagy.
In summary, our data reveal a potential novel role for myco-
bacterial nuoG in inhibition of LC3-mediated autophagic path-
ways, with relevance for protective immunity against M. tubercu-
losis. Even though the prominent long-term protective efficacy of
BCG ureC::hly of up to 2 logs over that of BCG set the bar high
for further improvement, we demonstrate a significant increase in
vaccine efficacy as reflected by a 5-fold-lower pulmonary M. tu-
berculosis burden upon deletion of nuoG from BCG ureC::hly,
corresponding with enhanced immune responses after vaccina-
tion and paralleled by an excellent safety profile.
MATERIALS AND METHODS
Bacterial strains and growth conditions. M. tuberculosis H37Rv (Amer-
ican Type Culture Collection; catalog no. 27294), M. tuberculosis Bei-
jing/W (RIVM catalog no. 17919; isolated in Mongolia), BCG Danish
1331 (BCG SSI) (American Type Culture Collection; catalog no. 35733),
BCG ureC::hly (5), and derivatives were grown in Middlebrook 7H9
broth (Becton, Dickinson) supplemented with albumin-dextrose-catalase
enrichment (Becton, Dickinson), 0.2% glycerol, and 0.05% Tween 80 or
on Middlebrook 7H11 agar (Becton, Dickinson) containing 10% (vol/
vol) oleic acid-albumin-dextrose-catalase enrichment (Becton, Dickin-
son) and 0.2% glycerol. Cultures were grown to mid-log phase in 1-liter
roller bottles at 37°C and 2 rpm. For vaccine stock preparations, log-phase
bacilli were harvested, washed with phosphate-buffered saline (PBS), and
stored at 	80°C in PBS-10% glycerol. Prior to vaccination, vials were
thawed, and cells were pelleted and administered as PBS suspensions. For
CFU estimation, serial dilutions were performed in PBS-0.05% Tween 80
(PBST) and dilutions were plated on Middlebrook 7H11 agar. Plates were
incubated at 37°C for 3 to 4 weeks prior to CFU counting.
Generation of recombinant BCG strains. The nuoG gene of BCG or
BCG ureC::hly was disrupted by site-directed mutagenesis. One-
kilobase fragments flanking nuoG were amplified by using PCR and spe-
cific oligonucleotides ko5=nuoG.fwd (5= ATCTTAAGTACGCGGTGAG
GTGGTG 3=)/ko5=nuoG.rev (5= TATCTAGAATTTCGACGCCGTCGA
T 3=) and ko3=nuoG.fwd (5= ATAAGCTTTCAATCACCTTGCCGTG 3=)/
ko3=nuoG.rev (5= TAACTAGTCTCGGCGAGCATGAACA 3=) (restric-
tion sites underlined) and inserted into pYUB854 (40). The knockout
plasmid was then electroporated into BCG or BCGureC::hly, and trans-
formants were selected on Middlebrook 7H11 agar supplemented with
80 g/ml hygromycin B. The resistance cassette was subsequently re-
moved by standard methods described previously (41). Site-directed mu-
tagenesis and resistance marker removal were confirmed by automated
sequencing of the nuo operon.
In vitro apoptosis and autophagy assays. Cells of the human mono-
cytic cell line THP-1 (American Type Culture Collection; catalog no.
TIB202; authenticated; tested for Mycoplasma contamination) were cul-
tured in RPMI 1640 medium (Gibco) containing 10% heat-inactivated
fetal bovine serum, 10 mM HEPES buffer solution, 1 mM sodium pyru-
vate, 2 mM L-glutamine, and penicillin-streptomycin (Pen-Strep). THP-1
monocytic cells were differentiated into macrophages in RPMI medium
containing 40 ng/ml phorbol myristate acetate (PMA) (Sigma) for 48 h.
BCG, BCG nuoG, BCG ureC::hly BCG, and BCG ureC::hly nuoG
were labeled red with the PKH26 linker kit (Sigma) and used to infect
THP-1 macrophages (multiplicity of infection [MOI] of 10, 20, and 100)
for 4 h. After 4 h, cells were washed 3 times with PBS to eliminate extra-
cellular BCG and fresh medium was added. For apoptosis, the assays were
performed in 96-well plates. After 24 and 48 h, activated caspases were
labeled with Cell Event Caspase-3/7 Green detection reagent with the
NucRed Live 647 ReadyProbes Reagent-1 kit (Life Technologies) for nu-
clear staining. For autophagy analysis, the THP-1 macrophages were dif-
ferentiated and infected on coverslips. After 4, 8, 24, and 48 h, treated cells
were washed with PBS and fixed with 4% paraformaldehyde (Electron
Microscopy Sciences). Fixed cells were washed with PBS, permeabilized
with 0.3% Triton X-100, and blocked with 1% bovine serum albumin
(BSA). Cells were incubated with anti-LC3-II antibody (Sigma L8918) at
room temperature for 1 h and then incubated with Alexa 488 anti-rabbit
IgG antibody (Life Technologies) for 30 min. Coverslips were mounted
using Hoechst mounting medium and evaluated on a confocal micro-
scope under oil with a 63 lens (Leica TCS SP-8). For quantification, 300
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individual infected cells were evaluated for each BCG strain in groups of
25, and the percentage of the 25 cells showing LC3 colocalization with
bacteria was plotted as one point.
Immune responses. Lymph nodes, spleens, and blood of vaccinated
C57BL/6 mice were collected at day 21. Single-cell suspensions were gen-
erated from lymph nodes and spleens in Iscove’s modified Dulbecco’s
medium (IMDM) 10% fetal calf serum (FCS) Pen-Strep, and flow cytom-
etry was performed to quantify cell populations. Details of antibodies used
are as follows: T cell panel, CD3 Alexa 700 (eBioscience; clone 17A2), CD4
phycoerythrin (PE)-Cy7 (BioLegend; clone RM4-5), CD8 V500 (BD Ho-
rizon, clone 53-6.7), CD62L allophycocyanin (APC) (BD Pharmingen;
clone MEL-14), CD44 Pacific Blue (in-house, clone IM7), CXCR5 PE (BD
Pharmingen; clone 2G8), CCR7 peridinin chlorophyll protein (PerCP)
(BioLegend; clone 4B12), PD-1 fluorescein isothiocyanate (FITC) (Bio-
Legend; clone 29F-1A12); B cell panel, B220 V500 (BD Horizon; clone
RA3-6B2), CD138 APC (BioLegend; clone 281-2), Fas-biotin (eBiosci-
ence; clone 15A7) with PerCP streptavidin (BD Bioscience), GL7 FITC
(BD Bioscience; clone GL7), major histocompatibility complex II (MHC-
II) Pacific Blue (BioLegend; clone M5/114.15.2). Central memory CD4
T cells were CD3 CD4 CD44high CD62high, effector memory CD4 T
cells were CD3 CD4 CD44high CD62Llow, T follicular helper cells were
CD44high CD62low CCR7low PD-1, and germinal center B cells were
B220GL7 Fas. For tetramer-based analysis of antigen-specific T cells,
I-Ab:Ag85B (positions 280 to 294; FQDAYNAAGGHNAVF) tetramers
were obtained from the National Institutes of Health (NIH) tetramer
facility (Bethesda, MD). A total of 10 nM Ag85B tetramer was added to
single-cell suspensions of pooled spleen and lymph nodes (LNs; cervical,
retromaxillary, inguinal, peripheral, and mesenteric) for 1 h at room tem-
perature. Tetramer cells were enriched as described elsewhere (42). In
brief, samples were incubated with magnetic antifluorochrome mi-
crobeads and concentrated by an LS column (Miltenyi Biotec), and the
resulting cell fractions were analyzed by flow cytometry. For intracellular
cytokine production, lymph node cells and splenocytes were plated over-
night with or without 10 g/ml M. tuberculosis H37Rv lysate (BEI Re-
sources; NR-14822) at 37°C. Brefeldin (Sigma) was added to lysate-
incubated samples, and PMA-ionomycin-brefeldin (all from Sigma) were
added to cells incubated with medium alone, for 4 h at 37°C. Following
this, cells were stained for surface markers, fixed with 2% paraformalde-
hyde, permeabilized with saponin buffer (saponin, 1 g/liter; CaCl2, 0.11 g/
liter; MgSO4, 0.125 g/liter; NaN3, 0.5 g/liter; bovine serum albumin [BSA]
1 g/liter; 10 mM HEPES in PBS, pH 7.4), and stained for intracellular
cytokine production. The intracellular cytokine panel consisted of CD3
Alexa 700 (eBioscience; catalog no. 56-0032082), CD4 Pacific Blue (BD
Pharmingen; catalog no. 588107), CD8 PerCP, and IFN-PE-Cy7. Sam-
ples were acquired on a fluorescence-activated cell sorting (FACS) LSR II
cytometer (BD Biosciences) using BD FACS Diva software and analyzed
using FlowJo v10 (TreeStar). Mycobacterium-specific antibodies in serum
were measured by indirect enzyme-linked immunosorbent assay (ELISA)
using M. tuberculosis H37Rv lysate (BEI Resources; NR-14822) and anti-
mouse IgG alkaline phosphatase (AP) (SouthernBiotech).
Histology and ex vivo apoptosis assays. Lymph nodes were collected
at days 0, 3, 7, and 14 postvaccination. Tissues were fixed in 4% formal-
dehyde in PBS and embedded in paraffin wax. Tissue sections were stained
with hematoxylin and eosin (H&E), and terminal deoxynucleo-
tidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) stain-
ing was performed for apoptosis (APO-BrdU TUNEL staining kit; Life
Technologies). Apoptotic cells were counted per field of view at 200
magnification.
Transcriptome analysis. Mice were vaccinated with BCG SSI, BCG
ureC::hly, or BCGureC::hlynuoG, and lymph nodes were collected in
RNAlater RNA stabilization reagent (Qiagen) at days 1, 3, and 7 postvac-
cination. Following the collection of all lymph nodes, samples were re-
moved from RNAlater, homogenized in Trizol (Qiagen) using a gen-
tleMACS dissociator (Miltenyi), and then frozen at	80°C. After thawing,
samples were allowed to stand at room temperature for 5 min, and then
precipitation was performed using isopropanol, ammonium acetate (Am-
bion AM9070G), and glycogen (Ambion AM9510), and pellets were
washed with 70% ethanol and resuspended in RNase-free water on ice.
The concentrations were measured on a NanoDrop spectrophotometer,
and the quality of the RNA was assessed using a Bioanalyzer. Agilent
whole-mouse-genome microarrays were performed using RNA samples
labeled with a one-color Quick Amp labeling kit (Agilent Technologies)
according to the manufacturer’s instructions. To avoid batch-specific ef-
fects, we spread samples from different groups and time points between
microarray chips. Scanning of microarrays was performed with 3-m
resolution and 20-bit image depth using a G2565CA high-resolution laser
microarray scanner (Agilent Technologies). Microarray image data were
analyzed and extracted with the Image Analysis/Feature Extraction soft-
ware G2567AA v.A.11.5.1.1 (Agilent Technologies) using the protocol
GE1_1105_Oct12 and recommended settings. Analysis of transcripts ob-
tained at day 1 after vaccination with BCG and BCG ureC::hly only, in
comparison to naive mice, was previously performed and published (7).
Here, microarray data obtained from all days and with all vaccine strains
were analyzed using GeneSpring 12.6 GX (Agilent Technologies), with
quality control filters, normalization, and one-way analysis of variance
(ANOVA). Naive mice were selected as the control group for comparative
analysis. The P values were corrected for multiple comparisons, and val-
ues of P  0.05 were considered statistically significant. Subgroups of
differentially expressed genes with change greater than 2-fold from the
comparison group (P  0.05) were used for generation of heat maps,
Venn diagrams, pathway analysis, and GO analysis. RT-PCR was per-
formed to validate expression of selected genes. cDNA was generated by
reverse transcription using the iScript cDNA synthesis kit (770-8897; Bio-
Rad), according to the manufacturer’s instructions, on a Gene Amp PCR
System 9700 machine (Applied Biosystems). PCR was performed on a
Step One Plus real-time PCR machine (Applied Biosystems) using the
SYBR green Fast mix (Thermo Fisher Scientific) with the Fast protocol
and the primers listed in Table S4 in the supplemental material. Primers
were designed using Primer3Plus software (43). Analysis was performed
using the threshold cycle (CT) comparative method (44), with the house-
keeping gene Ywhaz used for normalization.
Animal experimentation. Nine- to 10-week-old female mice (BALB/c
and CB-17/Icr-PrkdcSCID/Rj [Janvier]; C57BL/6 [Charles River Laborato-
ries]) were kept under specific-pathogen-free conditions in groups of five
in individually ventilated cages. Animals were vaccinated subcutaneously
in the tail base with 106 CFU of BCG strains. At designated time points
postvaccination, mice were euthanized and tissues of interest were re-
moved and homogenized in PBS-0.05% Tween 80 prior to CFU enumer-
ation or processed otherwise. For protective efficacy studies, mice were
aerosol challenged 90 days postvaccination with a low dose of 100 to
200 CFU of M. tuberculosis. All animal studies have been ethically re-
viewed and approved by the State Office for Health and Social Services,
Berlin, Germany. Experimental procedures were carried out in accor-
dance with the European directive 2010/63/EU on Care, Welfare and
Treatment of Animals.
Statistical methods. GraphPad Prism 6.04 (GraphPad Software, Inc.)
was used for statistical analysis. Survival curves were calculated by using
the Mantel-Cox log rank test. Vaccine efficacy was evaluated by one-way
ANOVA with Tukey’s multiple-comparison test. Similarity of variances
between groups compared was determined by the Brown-Forsythe test.
For autophagy quantification, the Mann-Whitney test was used for pair-
wise comparison. Two-way ANOVA with Tukey’s multiple-comparison
test was used to evaluate immunology data.
Microarray data accession number. Microarray data are available
from the NCBI GEO database under accession code GSE74282.
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